Johnson & Johnson $JNJ Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

Key Points

• MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Johnson & Johnson by 17.3%, acquiring an additional 56,040 shares, bringing their total holdings to 379,870 shares valued at approximately $62.99 million.
• Several institutional investors have also raised their stakes in Johnson & Johnson, with 69.55% of the company's stock now held by institutional investors.
• Wall Street analysts have given Johnson & Johnson a mixed rating, with the average sentiment describing it as a "Moderate Buy" and an average price target of $176.29.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 17.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 379,870 shares of the company's stock after purchasing an additional 56,040 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Johnson & Johnson were worth $62,987,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Lantz Financial LLC increased its position in Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after acquiring an additional 377 shares during the last quarter. Apexium Financial LP grew its holdings in shares of Johnson & Johnson by 10.7% in the first quarter. Apexium Financial LP now owns 23,989 shares of the company's stock worth $3,978,000 after purchasing an additional 2,310 shares during the last quarter. Joel Isaacson & Co. LLC grew its holdings in shares of Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after purchasing an additional 2,526 shares during the last quarter. State of Wyoming grew its holdings in shares of Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after purchasing an additional 10,279 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. grew its holdings in shares of Johnson & Johnson by 7.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock worth $12,164,000 after purchasing an additional 4,816 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded down $0.13 during trading on Monday, reaching $178.30. The company had a trading volume of 8,325,117 shares, compared to its average volume of 7,659,331. The firm's 50-day simple moving average is $168.57 and its 200 day simple moving average is $160.79. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market capitalization of $429.40 billion, a PE ratio of 19.07, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on JNJ shares. Guggenheim restated a "neutral" rating and issued a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Barclays upped their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Citigroup upped their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research note on Thursday, August 21st. Finally, Royal Bank Of Canada upped their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $176.29.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.